Mifegyne (Mifepristone)

Mifepristone blocks progesterone receptors in the uterine lining, causing decidual breakdown and detachment of the embryo. This antagonism also sensitises the uterus to prostaglandins, so when a prostaglandin such as misoprostol is given, strong uterine contractions expel the pregnancy tissue.

The exact dose of Mifegyne is determined by the prescribing clinician based on local guidelines and patient factors. Typically, a single oral dose is administered followed by a misoprostol regimen, but the prescriber sets the specific amount and timing.

Mifegyne is intended for use in early pregnancy termination and is not used to treat ongoing pregnancy beyond the approved indication. It is contraindicated in ongoing pregnancy beyond ten weeks and should be avoided during breastfeeding unless the prescriber determines that the benefit outweighs potential risk.

To order Mifegyne, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import paperwork.

The main alternative to Mifegyne in medical abortion is misoprostol alone, which is less effective without a progesterone antagonist. Combining Mifegyne with misoprostol yields higher success rates and fewer repeat procedures compared with misoprostol monotherapy, making the combination the preferred regimen for early medical abortion.

Mifegyne should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in areas with high humidity or direct sunlight.

Mifegyne is taken orally as a tablet. The patient swallows the tablet whole with water, usually in a clinical setting, followed by a prescribed misoprostol regimen after a specified interval to complete the abortion process.

The most serious risks associated with Mifegyne include heavy hemorrhage that may require transfusion, severe infection (sepsis), and allergic reactions that can progress to anaphylaxis. Patients should be instructed to seek immediate medical attention if they experience excessive bleeding, fever, or signs of an allergic reaction.

Mifegyne should not be used in individuals with known hypersensitivity to mifepristone, chronic adrenal insufficiency, long‑term corticosteroid therapy, anticoagulant therapy, ectopic pregnancy, intrauterine device in place, or when the gestational age exceeds ten weeks. Contraindications must be confirmed before prescribing.